CD47 and neoplasm: More specifically, exploring the utility of anti-CD47 treatments in conjunction with other tumor-specific opsonizing antibodies, radiation exposure, and immunosuppressive cell-depleting reagents will allow us to determine its full range of efficacy as an anti-tumor response [72,75].